MapLight Therapeutics Inc. shares jumped as much as 23% after the biotechnology firm raised $258.9 million in an initial ...

Inflammation biotech Evommune plans to take the leap into public waters with an expected initial public offering price of $15 ...

Evommune is set to make its stock market debut next week, but the biotech company is keeping investors guessing about its final share price.

MapLight Therapeutics is heading to the Nasdaq this morning via a $250 million IPO the biotech will use to advance its ...

The government shutdown has left the SEC quiet, but a Peninsula biotech managed to go public anyway, lighting a path to Wall ...

Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...

Navan will be the first large company to debut without a fully functioning Securities and Exchange Commission.

As the U.S. IPO market opens back up, here's how biotech CEO Marc de Garidel says business leaders can capitalize.

Illuminating its plans, neurological disease specialist MapLight said it would offer 14,750,000 shares of its common stock at $17.00 per share, which works out to an IPO of around $251m. The biotech ...

The China Securities Regulatory Commission (CSRC) issued new guidelines to reform the offline IPO placement mechanism, giving ...

We’ve also seen investors lean into neurodegenerative and CNS conditions like schizophrenia. Karuna’s $14 billion acquisition ...

New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative ...